ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1029

Recipient Age Is Significantly Associated with Immunological and Infective Complications Post Kidney Transplantation

Session Information

Category: Transplantation

  • 1702 Transplantation: Clinical and Translational

Authors

  • Hung, Rachel, Royal Free Hospital, London, London, United Kingdom
  • Basu, Sumoyee, Royal Free Hospital, London, United Kingdom
  • Goldet, Gabrielle, None, Boston, Massachusetts, United States
  • Fernando, Raymond, University College London, London, United Kingdom
  • De Serres, Sacha A., University Health Center (CHU) of Quebec, Laval University, Quebec, Quebec, Canada
  • Bass, Paul, Royal Free Hospital, London, United Kingdom
  • Harber, Mark, UCL centre for Nephrology, London, United Kingdom
  • Salama, Alan D., University College London, London, United Kingdom
  • Magee, Ciara N., None, Boston, Massachusetts, United States
Background

In recent years, there has been a marked increase in the number of older patients (> 65) undergoing kidney transplantation. While there is increasing evidence that the ageing immune system is characterised by immunosenescence, many centres do not have age-specific protocols for immunosuppression. In this study, we sought to examine the effect of recipient age on the development of complications of over- and under-immunosuppression post-transplantation.

Methods

We investigated the outcomes of 90 patients aged > 65 who underwent kidney transplantation in our centre between April 2009-March 2016, 42 of whom were aged >70; these patients were compared to 57 controls aged 18 – 64, who were matched for number of HLA mismatches. Recorded variables included % cRF pre-transplant, rejection, development of de novo donor-specific anti-HLA antibodies (DSA) and development of CMV viraemia post-transplantation.

Results

Interestingly, there were significant differences in the mean %cRF pre-transplant across the groups:18-34, 17.75%; 35-49, 29.65%; 50-64, 36.29%; 65-69, 17.1%; and >70, 8.4%; p=0.008. The rate of rejection was markedly increased in the control group compared to those aged > 65 years (19.3% vs. 11.1%), although this did not reach statistical significance. Conversely, rates of CMV viraemia were significantly elevated in recipients >65 when compared to recipients <65 (75.6% vs 50.9%, p=0.03). Rates of de novo Class I DSA were also significantly higher in the younger age groups (18.8%, 0% & 23.8% in patients aged 18-34, 35-49 & 50-64, compared to 4.2% & 7.1% in recipients aged 65-69 & >70, respectively; p=0.025), while the development of de novo Class II DSA followed a similar trend (6.3%, 20% & 14.3% in patients aged 18-34, 35-49 & 50-64, versus 2.1% & 4.8% in recipients aged 65-69 & >70, respectively; p=0.077).

Conclusion

These data indicate that older recipient age is associated with reduced rates of rejection and de novo DSA but significantly increased infectious complications post-transplantation. Given the significant morbidity consequent to over-immunosuppression, consideration should be given to the development of age-specific protocols for immunosuppression.